Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Fischer

Showing results (861-870 of 922) with videos related to

Pageof 93
Sort By:
Journal of Cancer Research and Clinical Oncology|May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJ C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
BMC Cancer|July 27, 2022
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancerG Sommerhäuser, A Kurreck, S Stintzing, et al.
Plos One|September 26, 2024
Impact of sinus surgery in people with cystic fibrosis and chronic rhinosinusitis in the era of highly effective modulator therapy: Protocol for a prospective observational studyChristine M Liu, Jakob L Fischer, Jeremiah A Alt, et al.
Plos Medicine|December 4, 2015
World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data SynthesisMartyn D Kirk, Sara M Pires, Robert E Black, et al.
British Journal of Cancer|November 22, 2012
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104S Boeck, A Jung, R P Laubender, et al.
ESMO Open|July 13, 2023
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)K Heinrich, M Karthaus, S Fruehauf, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)D P Modest, I Ricard, S Stintzing, et al.
Translational Neuroscience|January 29, 2024
Brain expression profiles of two <i>SCN1A</i> antisense RNAs in children and adolescents with epilepsyMarius Frederik Schneider, Miriam Vogt, Johanna Scheuermann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)M Michl, S Stintzing, L Fischer von Weikersthal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialS Stintzing, P Wirapati, H-J Lenz, et al.
Pageof 93

Showing results (861-870 of 922) with videos related to

Sort By:
Pageof 93
Journal of Cancer Research and Clinical Oncology|May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJ C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
BMC Cancer|July 27, 2022
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancerG Sommerhäuser, A Kurreck, S Stintzing, et al.
Plos One|September 26, 2024
Impact of sinus surgery in people with cystic fibrosis and chronic rhinosinusitis in the era of highly effective modulator therapy: Protocol for a prospective observational studyChristine M Liu, Jakob L Fischer, Jeremiah A Alt, et al.
Plos Medicine|December 4, 2015
World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data SynthesisMartyn D Kirk, Sara M Pires, Robert E Black, et al.
British Journal of Cancer|November 22, 2012
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104S Boeck, A Jung, R P Laubender, et al.
ESMO Open|July 13, 2023
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)K Heinrich, M Karthaus, S Fruehauf, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)D P Modest, I Ricard, S Stintzing, et al.
Translational Neuroscience|January 29, 2024
Brain expression profiles of two <i>SCN1A</i> antisense RNAs in children and adolescents with epilepsyMarius Frederik Schneider, Miriam Vogt, Johanna Scheuermann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)M Michl, S Stintzing, L Fischer von Weikersthal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialS Stintzing, P Wirapati, H-J Lenz, et al.
Pageof 93